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Abstract  
Background and purpose 
The FOCUS trial showed that fluoxetine did not improve modified Rankin scale scores 
(mRS) but increased the risk of fractures. We aimed to describe the fractures, their impact on 
mRS and factors associated with fracture risk 
Methods  
A UK, multicentre, parallel group, randomised, placebo-controlled trial. Patients  ≥18yrs with 
a clinical stroke and persisting deficit assessed two to 15 days after onset were eligible. 
Consenting patients were allocated fluoxetine 20mg or matching placebo for six months. The 
primary outcome was the mRS at six months and secondary outcomes included fractures.  
Results 
 Sixty five of 3127(2.1%) patients had 67 fractures within six months of randomisation; 43 
assigned fluoxetine and 22 placebo. Fifty nine (90.8%) had fallen and 26(40%) had fractured 
their neck of femur. The effect of fluoxetine on mRS (Common odds ratio (COR)=0.951) 
was not significantly altered by excluding fracture patients (COR=0.961). Cox proportional 
hazards modelling showed that only age >70yr (Hazard Ratio (HR)=1.97(95% CI 1.13 to 
3.45;p=0.017), female sex (HR=2.13(1.29 to 3.51;p=0.003) and fluoxetine  (HR=2.00(1.20 to 
3.34;p=0.008) were independently associated with fractures.  
Conclusions 
Most fractures resulted from falls. Although many fractures were serious, and likely to impair 
patients’ function, the increased fracture risk did not explain the lack of observed effect of 
  
fluoxetine on mRS. Only increasing age, female sex and fluoxetine were independent 
predictors of fractures.  
Clinical trial registration 
URL:http://www.controlled-trials.com. ISRCTN83290762 
  
  
Introduction  
Stroke survivors are at greater risk of fractures compared with stroke free individuals1. Many 
stroke survivors become depressed and are treated with selective serotonin reuptake inhibitors 
(SSRIs) which have been associated with higher risk of bone fractures in observational studies.2 
Mechanisms include increased risk of falling as well as effects of stroke and SSRIs on bone 
density.3 These observational studies are confounded by indication, since depression is 
associated with increased fractures risk.4 
The FOCUS trial aimed to establish whether fluoxetine improved the functional outcome 
(mRS) after stroke. It demonstrated no significant difference in mRS but fewer patients 
allocated  fluoxetine developed new depression during six month treatment period (13.43% 
vs 17.21%; p=0.0033) and more patients in the fluoxetine group had fractures (2.88% vs 
1.47%; p=0.0070)5. 
 
The FOCUS trial results strongly suggest that fluoxetine actually causes fractures. In these 
exploratory analyses of the FOCUS data we aimed to address the following questions: 
1. What sites did fractures affect? 
2. Did the excess of fractures obscure beneficial effects of fluoxetine on mRS? 
3. What baseline factors were associated with fractures? 
4. Does the timing of fractures provide clues to the potential mechanisms of SSRI 
induced fractures? 
Methods 
The data that support the findings of this study are available from the corresponding author 
upon reasonable request. FOCUS was a multicentre, parallel group, randomised, placebo-
  
controlled trial which enrolled 3,127 patients in 103 UK hospitals. Patients ≥18 years old, 
with a stroke and focal neurological deficits persisting at two to15 days after onset were 
eligible. Consenting patients were randomly allocated fluoxetine 20 mg or matching placebo 
for six months. The primary outcome was the mRS, at six months. Patients, carers, health-
care staff, and the trial team were blinded to treatment allocation. Details of fractures 
confirmed on X-Rays, were sought at hospital discharge and six months follow up. The 
Scotland A Multicentre Research Ethics Committee approved the protocol on Dec 
21,2011. Written consent was obtained from all patients, or a proxy if they lacked 
capacity. 
We compared the number of fractures occurring in those with and without specific 
characteristics (table 1) and formally tested each variable by plotting time to fracture on 
Kaplan-Meier survival curves in those with and without each characteristic and compared these 
with the log-rank statistic. We included all variables with a p<0.1 into a Cox proportional 
hazards model to identify independent predictors of fracture risk.  
Results 
Sixty five of the 3127(2.1%) patients enrolled had 67 definite new fractures (two patients 
sustained more than one fracture simultaneously) within six months of randomisation. This 
analysis excludes three patients reported previously whose fractures may have been present at 
randomisation.5 Of the 67, 59(90.8%) resulted from a fall. The most common fracture sites 
were: neck of femur 26(40%), vertebral 10(15%), and wrist 7(11%) with 40(62%) affecting 
sites associated with osteoporosis.  
  
Removing the 65 patients with a fracture from the primary analysis did not significantly alter 
the estimate of effect of fluoxetine on mRS (COR including fractures 0.951(95% CI 0.839 to 
1.079];p=0.439) and 0.961(95% CI 0.847 to 1.093;p=0.545) without fractures).  
Patients with fractures were older (mean age(sd) 76.2(11.6) vs 71.3(12.2), difference in mean 
4.9(95% CI 2.0 to 7.9) p= 0.0012) but had similar NIHSS scores (median 7(IQR 4,11) vs 
6(3,11), p=0.4065). The baseline characteristics of those with and without fractures are shown 
in Table 1. The Cox proportional hazards model showed that only age >70yr (Hazard Ratio 
(HR)=1.97(95% CI 1.13 to 3.45; p=0.017), female sex (HR=2.131 (1.294 to 3.511; p=0.003) 
and fluoxetine treatment (HR=2.00 (1.196 to 3.344;p=0.0082) were independent predictors of 
fracture (Table 2). The Kaplan Meier curve comparing fracture risk in the two treatment groups 
is shown in the Figure.  
Discussion 
The most common site of fracture was neck of femur, and most were in sites associated with 
osteoporosis; and almost all resulted from a fall. Removing patients who had fractures between 
randomisation and six months from our primary analysis did not greatly alter our estimate of 
the effect of fluoxetine on mRS. Older age, female gender and fluoxetine were independent 
predictors of subsequent fractures. An increased risk of falling is likely to explain much of the 
excess risk because most fractures were associated with a fall, falls with injury were more 
common in the fluoxetine group (120(7.67%) vs 94(6∙01%) p=0.0663)5 and the risks in the two 
treatment groups diverged early after randomisation (figure). No other baseline factors 
analysed had statistically significant associations with fracture risk. 
Our analyses do not support the hypothesis that loss of function due to the excess of fractures 
in the fluoxetine group might explain the lack of improvement in functional outcomes observed 
  
in the trial. Our finding that greater age, and female gender are associated with fracture risk 
confirms the findings of observational studies.1 This might be due to effects on cognition, 
coordination, balance, or activity levels on falls but we cannot exclude a contribution from 
fluoxetine’s possible effect on bone density. 
These exploratory analyses have limitations. The number of falls and fractures were modest 
limiting the power of these analyses. We did not collect many data items at baseline (e.g. 
balance), during the treatment period (activity, cognition) or at the time of a fall or 
fracture (e.g. current medication) which could have been associated with falls and/or 
fracture risk because these outcomes were not the focus of our trial.  Our only baseline 
indicators of bone density were previous fractures and the use of medications at baseline to 
reduce bone loss. Also, we did not systematically collect fractures beyond six months so cannot 
determine whether the effect of fluoxetine on fracture risk persists, as it might if it causes 
osteoporosis, or whether the risk subsides after stopping if it acted by causing falls directly, or 
indirectly. 
The ongoing AFFINITY and EFFECTS trials will provide an opportunity to confirm our 
findings and further explore the mechanisms of fractures.5 The risk of fractures with fluoxetine, 
especially in older female patients, needs to be considered when making decisions to use it 
after stroke.  
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Figure Legend 
Kaplan-Meier curves comparing the risk of fracture in those allocated fluoxetine and placebo 
. 
  
  
Table 1. The baseline characteristics of patients with and without  fracture and Log rank 
statistic to provide a p value for the difference in Kaplan-Meier curves in those with and 
without each characteristic. 
 No fracture Fracture Log-rank 
Patient characteristics N % N % Statistic (p) 
All patients 3062 100.0 65 100.0  
Randomised treatment      
Fluoxetine 1521 49.7 43 66.2 0.0084 
Placebo  1541 50.3 22 33.9  
Sex      
Female 1167 38.1 38 58.5 0.0005 
Male  1895 61.9 27 41.5  
Age group      
≤70 years old 1313 42.9 17 26.2 0.0033 
>70 years old  1749 57.1 48 73.9  
Before the stroke      
Dependent in activities of daily living  253 8.3 8 12.3 0.1762 
Ischaemic stroke/TIA 557 18.2 11 16.9 0.8817 
Diabetes 628 20.5 12 18.5 0.7603 
Bone fractures 486 15.9 11 16.9 0.8285 
Depression 244 8.0 9 13.9 0.0913 
Stroke type      
 Intracerebral haemorrhage 301 9.8 10 15.4 0.1320 
Stroke deficits at baseline      
  
Unable to walk 2227 72.7 53 81.5 0.0849 
Unable to lift both arms 1243 40.6 25 38.5 0.8704 
Cannot talk 779 25.4 18 27.7 0.5203 
Motor deficit on NIHSS 2665 87.0 57 87.7 0.7967 
Visual field deficit on NIHSS 844 27.6 14 21.5 0.3261 
Limb ataxia on NIHSS 753 24.6 17 26.2 0.8323 
Baseline medications      
Non SSRI anti-depressant 137 4.5 5 7.7  
Treatments for Osteoporosis  287 9.4 5 7.7  
Major or minor tranquillisers 121 4.0 3 4.6  
Parkinsons disease medication 14 0.5 2 3.1  
BP lowering medication 2178 71.1 52 80.0 0.1000 
Treatments for vertigo 129 4.2 5 7.7  
Any of these drugs of interest  2349 76.7 55 84.6 0.1161 
 
 
 
  
  
Table 2.  Cox proportional hazards models. 
Variables Value Pr>ChiSq Hazard 
Ratio 
95%CI 
    Lower Upper 
Model including all variables      
Sex Female 0.0082 1.978 1.193 3.280 
Age >70 years old 0.0181 1.973 1.123 3.467 
Previous depression No/UK 0.1348 0.581 0.285 1.184 
Able to walk No 0.2396 1.462 0.776 2.755 
Randomised treatment Fluoxetine 0.0086 1.992 1.191 3.330 
Final model      
Sex Female 0.0030 2.131 1.294 3.511 
Age >70 years old 0.0174 1.972 1.127 3.451 
Randomised treatment Fluoxetine 0.0082 2.000 1.196 3.344 
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